Professor Ed Gane says that there is no need for liver biopsy for assessing staging of hepatitis C in New Zealand. 

The cost of the flight within New Zealand to a liver clinic with a fibroscan is justified, he believes. 

Patients don't want a biopsy, and fibroscan has shown itself to be an effective tool for assessing fibrosis.